<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACRVM</journal-id><journal-title-group><journal-title>Asian Case Reports in Vascular Medicine</journal-title></journal-title-group><issn pub-type="epub">2326-3490</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACRVM.2017.52002</article-id><article-id pub-id-type="publisher-id">ACRVM-20798</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACRVM20170200000_47162793.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  急性心肌梗塞合并心功能不全的诊疗进展
  Diagnosis and Treatment Progress in Cardiac Insufficiency with Acute Myocardial Infarction
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>梅</given-names></name><xref ref-type="aff" rid="aff1"><sub>1</sub></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>安徽医科大学第三附属医院第一人民医院集团滨湖医院心内科，安徽 合肥</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>lmsgfsq@163.com</email></corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>05</month><year>2017</year></pub-date><volume>05</volume><issue>02</issue><fpage>7</fpage><lpage>14</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   急性心肌梗塞常合并有急性心功能不全和(或)左室功能下降，对于心肌梗死后期的心功能不全发生率，短期及长期的致死率有显著影响。研究发现及时开通急性心肌梗死患者罪犯血管(溶栓或急诊PCI或溶栓后PCI，搭桥治疗)，急性心肌梗死合并心功能不全发生率明显下降，仍有一部分急性心肌梗死患者合并有急性心功能不全及(或)左室功能不全，且这两种并发症常并存，互相影响，导致急性心肌梗死后“存活”患者的心功能不全的发生率增加。如何预防心肌梗死后急性心功能不全的发生，目前仍是临床关注的问题。下面就急性心肌梗塞合并心功能不全的流行病学，分型，机制等方面进行综述。 Acute myocardial infarction is often accompanied with acute cardiac inefficiency and/or left ventricular dysfunction that affects the incidence of cardiac insufficiency and short term and long-term mortality. The study found that the timely opening of blood vessels (thrombolysis or emergency PCI or thrombolysis after PCI, bypass treatment), in acute myocardial infarction pa-tients with acute myocardial infarction, remarkably reduce the acute cardiac inefficiency and/or left ventricular insufficiency, but there are still some patients with acute myocardial infarction have acute cardiac incomplete function and/or left ventricular dysfunction, these two complica-tions often coexist, and affect each other, leading to acute myocardial infarction “surviving” pa-tients increasing incidence of cardiac insufficiency. How to prevent the incidence of acute cardi-ac insufficiency in myocardial infarction patients which is focus in clinical. The overview is about the epidemiology, typing, and mechanisms of acute myocardial infarction with acute cardiac insufficiency. 
   

  
 
</p></abstract><kwd-group><kwd>综述，急性心肌梗死，心功能不全, Overview</kwd><kwd> Acute Myocardial Infarction</kwd><kwd> Cardiac Insufficiency</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>急性心肌梗塞合并心功能不全的诊疗进展<sup> </sup></title><p>刘梅</p><p>安徽医科大学第三附属医院第一人民医院集团滨湖医院心内科，安徽 合肥</p><p>收稿日期：2017年5月11日；录用日期：2017年5月28日；发布日期：2017年5月31日</p><disp-formula id="hanspub.20798-formula8"><graphic xlink:href="http://html.hanspub.org/file/1-2470052x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>急性心肌梗塞常合并有急性心功能不全和(或)左室功能下降，对于心肌梗死后期的心功能不全发生率，短期及长期的致死率有显著影响。研究发现及时开通急性心肌梗死患者罪犯血管(溶栓或急诊PCI或溶栓后PCI，搭桥治疗)，急性心肌梗死合并心功能不全发生率明显下降，仍有一部分急性心肌梗死患者合并有急性心功能不全及(或)左室功能不全，且这两种并发症常并存，互相影响，导致急性心肌梗死后“存活”患者的心功能不全的发生率增加。如何预防心肌梗死后急性心功能不全的发生，目前仍是临床关注的问题。下面就急性心肌梗塞合并心功能不全的流行病学，分型，机制等方面进行综述。</p><p>关键词 :综述，急性心肌梗死，心功能不全</p><disp-formula id="hanspub.20798-formula9"><graphic xlink:href="http://html.hanspub.org/file/1-2470052x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2017 by author and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="http://image.hanspub.org:8080\Html/htmlimages\1-2890033x\e70a10f1-7c93-45ea-9603-062237856e4b.png" /><img src="http://image.hanspub.org:8080\Html\htmlimages\1-2890033x\e898c85e-ffc4-45c9-b817-14224a4d6960.png" /></p></sec><sec id="s3"><title>1. 流行病学</title><p>有流行病学研究发现急性心肌梗塞患者不管采取哪种方式干预，住院期间急性心功能不全或左室功能下降还是经常发生。在1975年至1995年期间WHAS研究对6789例急性心肌梗死的患者进行比较完整的随访，发现其中有38%患者发生急性心功能不全，还发现90年急性心肌梗塞伴发急性心功能不全的发生率与70年代中期相比有明显的下降 [<xref ref-type="bibr" rid="hanspub.20798-ref1">1</xref>] 。然而有资料显示在2009~2012年期间心肌梗塞患者住院期间的死亡率下降，心功能不全的发生率却稍有升高 [<xref ref-type="bibr" rid="hanspub.20798-ref2">2</xref>] ，可能与急性心肌梗塞患者住院期间罪犯血管得到及时开通，急性心肌梗塞后存活率提高有关。</p></sec><sec id="s4"><title>2. 急性心肌梗塞合并心功能不全的分型及机制</title><sec id="s4_1"><title>2.1. 急性心肌梗塞伴发急性心功能不全分类</title><p>1) 无心功能不全的临床表现，客观检查有左室收缩功能下降；2) 有急性心功能不全的临床症状，而相关检查提示左室收缩功能基本正常；3) 有心功能不全临床表现，同时合并有左室收缩功能障碍检查结果。</p></sec><sec id="s4_2"><title>2.2.急性心肌梗塞合并急性心功能不全的机制</title><p>急性心肌梗塞合并急性心功能不全的机制比较复杂，涉及分子学，细胞学及形态学等。有研究发现首次发生急性心肌梗死伴发急性心功能不全的发生率为20%，其中约有9%后来发展为心功能不全 [<xref ref-type="bibr" rid="hanspub.20798-ref3">3</xref>] 。其中约10%~20%的患者为暂时性的，再次发生心肌梗塞的患者心功能不全多发生在急性心肌梗塞后的最初几天。主要机制为心肌顿抑，很大程度上依赖心肌再灌注，另外急性心肌梗塞引起的心脏结构异常，如乳头肌功能失常，二尖瓣反流，猝发心律失常如快室率性心律失常如心房纤颤等常诱发急性心功能不全。</p></sec><sec id="s4_3"><title>2.3. 急性心肌梗死后慢性心功能不全的影响</title><p>急性心肌梗死后慢性心功能不全的发生多由于心室重构引起，左心室发生重构是指左室的形状和结构的变化，导致心脏形状，大小功能异常。有报道心肌重构发生在心肌梗塞后6周内；在心肌梗塞后心功能不全的发生发展过程中心肌细胞可能起着重要的作用，包括心肌细胞的坏死、凋亡、顿抑、肥大及心肌重构。心肌细胞肥大，胶原蛋白积聚，结果导致室壁变薄，心功能下降。</p></sec><sec id="s4_4"><title>2.4. 心肌重塑过程受多重因素影响</title><p>心肌重塑过程受多重因素影响，如血流动力学的变化，神经体液因子的激活，心肌成纤维细胞，细胞外基质等也起着重要作用。在多种神经体液中血管紧张素II、醛固酮、内皮素-1、去甲肾上腺素等，特别是肾素血管紧张素系统中血管紧张素II 引起的心肌细胞的肥大，纤维化，胶原蛋白的沉积，引起心肌重构，内皮因子-1也有类似的作用，其他细胞因子如肿瘤坏死因子TNF-α，白细胞介素(IL)-6，生长因子如成纤维生长因子，细胞转化生长因子，血小板诱导的生长因子 [<xref ref-type="bibr" rid="hanspub.20798-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.20798-ref4">4</xref>] 。金属蛋白酶系列中如MMPs在心肌急性梗塞后重塑中起着重要的作用 [<xref ref-type="bibr" rid="hanspub.20798-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.20798-ref5">5</xref>] 。</p></sec></sec><sec id="s5"><title>3. 诊断急性心肌梗塞的早期生物学标记物</title><sec id="s5_1"><title>3.1. 诊断急性心肌梗死的生物学标记物</title><p>肌钙蛋白及肌酸激酶同工酶是目前公认的诊断急性心肌梗塞标记物。肌钙蛋白是从不可逆损伤的心肌细胞中释放，肌钙蛋白的水平是由坏死心肌细胞数目多少决定。其高峰值在急性心肌梗塞12小时出现，持续半月左右，再灌注治疗的临床应用，肌钙蛋白在临床的价值下降，目前超敏肌钙蛋白的临床应用，能够更早的诊断急性心肌梗塞，指导临床 [<xref ref-type="bibr" rid="hanspub.20798-ref4">4</xref>] - [<xref ref-type="bibr" rid="hanspub.20798-ref8">8</xref>] 。2014美国急性冠脉综合征的诊疗建议及我国2012年急性冠脉综合征的诊疗指南均对超敏肌钙蛋白的临床地位予以肯定。</p></sec><sec id="s5_2"><title>3.2. 垂体后叶素</title><p>垂体后叶素通过V1受体增加外周血管活性，增加心脏后负荷及血管阻力，提高肌内蛋白的合成 ，促使心室肌细胞肥大，同时作用于肾小管的V2受体，引起水潴留。低水平的垂体后叶素可以排除超敏肌钙蛋白T阴性的急性心肌梗死。目前垂体后叶素已被肽素代替应用于临床，当肽素&lt;14 pg/ml,且肌钙蛋白&lt;0.01 ng/ml, 同时ROC曲线下面积为0.97时可以排除急性心肌梗死，由于垂体后叶素缺乏临床特异性，很少应用于临床诊断急性心肌梗死。</p></sec><sec id="s5_3"><title>3.3. Heart-Type Fatty Acid Binding Protein (H-FABP)</title><p>H-FABP是心肌脂肪代谢过程中产生的。在脑，肾脏及骨骼肌及缺血性卒中也产生少量的FABP，在心肌梗塞早期迅速释放至胞液。有研究提示FABP是老鼠体内急性局部缺血的早期标记物，然而也有研究表明FABP对早期诊断急性心肌梗塞没有价值。有研究提示FABP水平对心肌梗塞的患者10个月心衰发生率及心肌梗塞后综合死亡终点有着密切的联系 [<xref ref-type="bibr" rid="hanspub.20798-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.20798-ref9">9</xref>] 。</p></sec></sec><sec id="s6"><title>4. 急性心肌梗塞患者心功能不全监测</title><p>除常规对急性心肌梗死患者的GRACE评分预测患者心功能不全的发生，还有下面介绍的几种：</p><sec id="s6_1"><title>4.1. BNP或NT-pro BNP</title><p>BNP或NT-pro BNP是一种氨基酸代谢的产物，在血液中浓度比较稳定，主要是由心室肌在容量增多及压力增大促使其合成和分泌增加，血浆BNP水平直接准确反映急性急性心肌梗死患者心功能,有助于早期发现急性心肌梗死患者心功能不全，与心衰发生的概率，左室重构的程度，左室射血分数有明显的相关性，对心肌梗塞后心功能不全的发生率和1年的死亡率预测远远超过score积分 [<xref ref-type="bibr" rid="hanspub.20798-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.20798-ref10">10</xref>] 。</p></sec><sec id="s6_2"><title>4.2. 高敏C-反应蛋白</title><p>冠心病的发生发展有研究证实与炎症有一定的关系，有研究表明血液中高水平的超敏C-反应蛋白与冠心病发生发展有着重要的关联，在急性心肌梗塞后12~24小时之间，超敏C-反应蛋白水平能预测肌梗塞后心功能不全及死亡的发生 [<xref ref-type="bibr" rid="hanspub.20798-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.20798-ref11">11</xref>] 。心肌梗塞早期超敏C-反应蛋白水平是预测心室心肌重构的独立危险因子 [<xref ref-type="bibr" rid="hanspub.20798-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.20798-ref12">12</xref>] ，但不能预测再次发生心肌梗塞，超敏C-反应蛋白浓度在心肌梗塞12周后其浓度下降至正常水平后才能再次预测急性心肌梗塞事件是否再次发生。</p></sec><sec id="s6_3"><title>4.3. Pregnancy associated Plasma Protein A (PaPPA)</title><p>Pregnancy associated Plasma Protein A (PaPPA)是一种金属蛋白酶，在不稳定斑块及细胞基质中水平较高，PaPPA在不稳定性心绞痛，急性心肌梗死患者血液浓度较高，与胰岛素样因子−1及超敏C-反应蛋白同时升高，与肌钙蛋白水平升高不一致。有研究提示急性心肌梗死早期PaPPA浓度明显升高，对于早期诊断急性心肌梗，甚至比肌钙蛋白浓度升高的更早，更快 [<xref ref-type="bibr" rid="hanspub.20798-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.20798-ref13">13</xref>] 。近期研究提示与超敏肌钙蛋白比较，PaPPA在胸痛的患者中早期诊断急性心肌梗死价值不如超敏肌钙蛋白 [<xref ref-type="bibr" rid="hanspub.20798-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.20798-ref14">14</xref>] 。在不稳定性粥样斑块患者中，包括颈动脉斑块，超敏C-反应蛋白及PaPPA升高，是心血管疾病死亡的独立预测危险因子， PaPPA预测心功能不全的发生敏感性不如超敏C-反应蛋白。</p></sec><sec id="s6_4"><title>4.4. 其他因子</title><p>如MMP9，MMP2，TIMP1等，其中TIMP1和MMP9是心血管相关死亡，心功能不全，或两者的独立危险因子，MMP2也在心肌梗塞后升高，是预后不良的对立危险因子，MMP9在急性心肌梗塞患者中水平较高，在心肌梗塞后心肌重塑中起着重要的作用 [<xref ref-type="bibr" rid="hanspub.20798-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.20798-ref5">5</xref>] Growth Differentiation Factor-15, ST2, Mid-Re- gional-Adrenomedullin (MRproADM),在临床中应用不多 [<xref ref-type="bibr" rid="hanspub.20798-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.20798-ref15">15</xref>] .</p></sec><sec id="s6_5"><title>4.5. 心脏超声检查</title><p>心脏超声在急性心肌梗塞患者早期诊断，血流动力学及并发症监测，左心室的重构及心肌梗塞后的近期及远期预后判断有着重要的地位 [<xref ref-type="bibr" rid="hanspub.20798-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.20798-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.20798-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.20798-ref17">17</xref>] 。左室射血分数是预测首次ST段抬高型心肌梗塞后住院期间心功能不全发生的独立危险因子 [<xref ref-type="bibr" rid="hanspub.20798-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.20798-ref18">18</xref>] 。</p></sec><sec id="s6_6"><title>4.6. 低脉压</title><p>在急性心肌梗塞后心功能不全患者中低脉压是预测心功能2~4级患者发生死亡的独立危险因子，脉压小的心功能不全患者是死亡率较高，与脉压正常者比较有显著统计学差异 [<xref ref-type="bibr" rid="hanspub.20798-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.20798-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.20798-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.20798-ref20">20</xref>] 。</p></sec></sec><sec id="s7"><title>5. 急性心肌梗塞合并心功能不全及左室重构的干预措施</title><sec id="s7_1"><title>5.1. 介入治疗</title><p>多个大型临床研究提示尽快开通闭塞的血管如溶栓治疗，急诊PCI，急诊冠状动脉搭桥，改善心肌灌注，减少心肌顿抑，从而挽救心肌，降低急性心肌梗塞后心功能不全的发生率 [<xref ref-type="bibr" rid="hanspub.20798-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.20798-ref21">21</xref>] 。随着冠脉介入技术的发展及普及，目前溶栓治疗的患者人数较急诊PCI人数明显减少。</p></sec><sec id="s7_2"><title>5.2. 药物</title><sec id="s7_2_1"><title>5.2.1. ACEI</title><p>ACEI类药物主要机制为改善心肌重塑，减轻心肌过度扩张而减少充盈性心力衰竭的发生和病死率。几项大规模临床随机试验如SIS-4，GISSI-3，SMILE，CCS-1，试验结果已明确提示在AMI早期使用ACEI类药物能降低病死率，尤其是明显降低前6周的病死率，而前壁心肌梗死伴有左室功能不全的患者获益最大，在无禁忌症的情况下尽早使用ACEI类药物，一般情况下在急性心肌梗死早期从小剂量开始，治疗上剂量应个体化。</p></sec><sec id="s7_2_2"><title>5.2.2. 倍他受体拮抗剂</title><p>该类药物已被证实是改善心肌梗塞患者预后的药物，目前急性心肌梗塞指南建议只要无禁忌症，急性心肌梗塞的患者倍他受体拮抗剂必须尽早应用。其作用机制通过减慢心率，降低体循环血压和减弱心肌收缩力减少心肌氧耗量，改善缺血区的心肌氧供需平衡，减少心肌坏的数目，缩小心肌梗死面积，降低急性期病死率有肯定的疗效 [<xref ref-type="bibr" rid="hanspub.20798-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.20798-ref22">22</xref>] 。</p></sec><sec id="s7_2_3"><title>5.2.3. 血BNP拮抗剂重组人脑利钠肽</title><p>近几年重组人脑利钠肽治疗急性心肌梗死后心功能不全的临床研究表明对于急性心肌梗死引起的急性心功能不全疗效肯定，已被越来越多的应用于临床改善急性心肌梗死患者心功能及生活质量，降低患者住院期间心功能不全的发生率及致死率，然而，同时也有临床研究表明重组人脑利钠肽在治疗急性心肌梗死后心功能不全效果受血BNP浓度的影响，在BNP ≤ 3000 pg/ml时比传统的多巴胺药物效果好，而当BNP浓度&gt;3000 pg/ml时疗效不比多巴胺效果佳 [<xref ref-type="bibr" rid="hanspub.20798-ref21">21</xref>] [<xref ref-type="bibr" rid="hanspub.20798-ref23">23</xref>] 。</p></sec><sec id="s7_2_4"><title>5.2.4. 螺内酯治疗急性心肌梗塞</title><p>螺内酯治疗急性心肌梗塞后心功能不全住院期间全因死亡率及因心血管疾病合并心功能不全的再住院率，在心肌梗死亚组中的益处也可见，包括已给以ACEI (ARBS)，倍他受体拮抗剂，阿司匹林，他汀类药物，冠状动脉再灌注治疗。</p></sec><sec id="s7_2_5"><title>5.2.5. 左西孟旦</title><p>一种钙离子增敏剂，其机制通过与心肌细胞的超敏肌钙蛋白C结合，促进心肌细胞收缩，另外通过增加ATP敏感的钾离子通道舒张血管，轻度抑制磷酸二酯酶的活性改善患者的心输出量，和每搏输出量，降低肺动脉锲压，体循环和肺循环的阻力，可以和倍他受体拮抗剂联合应用，且不增加患者的死亡率 [<xref ref-type="bibr" rid="hanspub.20798-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.20798-ref23">23</xref>] [<xref ref-type="bibr" rid="hanspub.20798-ref24">24</xref>] [<xref ref-type="bibr" rid="hanspub.20798-ref25">25</xref>] 。</p></sec><sec id="s7_2_6"><title>5.2.6. 其他</title><p>其他也有报道辛伐他汀调脂治疗对急性心肌梗塞后治疗心功能不全的发生率，(4s)，后来CARE试验普伐他汀并没有对照剂减少心衰的发生率。抗血小板治疗目前尚未有系统的评估研究，有临床研究提示急性心肌梗塞后心室起搏能减少急性心肌梗塞后患者的心功能不全的发生率。对于合并有急性心功能不全伴低血压者近几年有临床研究报道通过血液透析疗法治疗和改善患者预后 [<xref ref-type="bibr" rid="hanspub.20798-ref24">24</xref>] [<xref ref-type="bibr" rid="hanspub.20798-ref26">26</xref>] 。</p></sec></sec><sec id="s7_3"><title>5.3. 药物与手术同时应用改善心肌梗死患者心功能</title><p>一项1198例急性前降支心肌梗塞患者临床研究提示对于心肌梗塞后心功能不全给以药物治疗的同时联合外科手术切除疤痕，改善心肌重构，改善左心功能，这个实验随访5年，在该研究中患者左室大小在60 ml/m<sup>2</sup>的患者被排除在外。其原理是急性心肌梗塞后心功能不全的发生是心室重塑的唯一结果，而心肌重塑主要因为心肌梗塞后疤痕组织无生命功能，激活神经内分泌系统活性，药物只是减少重构的程度，不能改变疤痕的大小及面积。手术治疗能切除无功能的疤痕组织，减少疤痕引起的内分泌神经系统激活，减少左室容积，增加左室射血分数，改善患者心肌梗塞后5年生存质量，但未有得到进一步验证和临床应用。</p><p>也曾有动物试验研究给以急性心肌梗塞的动物心脏置入心脏支持装置CSD (cardiac support device)，该装置在心脏外表，防止心脏扩大，研究结果提示两组之间在左心室大小，左室射血分数，左室收缩力均有显著统计学差异，心肌梗塞组左室心肌的倍他受体、肾上腺素受体敏感性下降，而置入CSD组反应正常。CSD装置能改善急性心肌梗塞后患者的左室重构，有待于进一步研究及推广。</p><p>曾有造血干细胞治疗ST段抬高型急性心肌梗塞后心功能不全的报道，临床效果肯定，副作用较小，改善患者的心肌重构及左室张力，修复损伤的心肌等 [<xref ref-type="bibr" rid="hanspub.20798-ref25">25</xref>] [<xref ref-type="bibr" rid="hanspub.20798-ref27">27</xref>] 后期也有相似的报道 [<xref ref-type="bibr" rid="hanspub.20798-ref26">26</xref>] [<xref ref-type="bibr" rid="hanspub.20798-ref28">28</xref>] 。另外有报道体母细胞也可以用来治疗急性心肌梗死后心功能不全，其疗效不亚于造血干细胞 [<xref ref-type="bibr" rid="hanspub.20798-ref27">27</xref>] [<xref ref-type="bibr" rid="hanspub.20798-ref29">29</xref>] ，这一结果令人兴奋，有待于进一步临床试验研究证实，临床上目前尚未把干细胞移植作为常用的方法。</p><p>目前采用常规药物治疗的基础上采用主动脉球囊反搏及左室辅助装置(LVAD)，及体外膜肺氧和支持技术(cemo)协助治疗患者的急性心肌梗塞后急性心功能不全，技术现已经非常成熟，在2106年欧洲急性心衰诊疗指南中地位得到肯定。</p></sec></sec><sec id="s8"><title>6. 总结</title><p>综上所述，目前有多种生物标记物应用于临床，如超敏C反应蛋白，超敏肌钙蛋白及BNP的临床应用，对于提高临床诊断及治疗提供了很大的帮助，但每种检测手段都有一定的局限性，而且急性心肌梗死后心功能不全的发生，对患者生活质量影响较大，也给个人及国家带来较大的经济负担，在临床上联合应用多标记物有助于观察患者的病情，检测患者病情变化趋势，弥补每项检测指标的缺陷，为临床诊断及治疗的决策提供正确的方向，使患者得到最大的获益。</p></sec><sec id="s9"><title>7. 展望</title><p>随着科学技术的发展，各种检测手段的进步，越来越多的能够检测急性心肌梗死的早期生物标记物应用于临床，为更早期的干预急性心肌梗死伴发心功能不全的治疗措施应用临床带来可能。</p></sec><sec id="s10"><title>文章引用</title><p>刘 梅. 急性心肌梗塞合并心功能不全的诊疗进展Diagnosis and Treatment Progress in Cardiac Insufficiency with Acute Myocardial Infarction[J]. 亚洲心脑血管病例研究, 2017, 05(02): 7-14. http://dx.doi.org/10.12677/ACRVM.2017.52002</p></sec><sec id="s11"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.20798-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Spencer, F.A., Meyer, T.E., Goldberg, R.J., et al. (1999) Twenty Year Trends (1975-1995) in the Incidence, In-Hos- pital and Long-Term Death Rates Associated with Heart Failure Complicating Acute Myocardial Infarction—A Community-Wide Perspective. Journal of the American College of Cardiology, 34, 1378-1387.</mixed-citation></ref><ref id="hanspub.20798-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Suter, L.G., Li, S.-X., Grady, J.N., et al. (2013) National Patterns of Risk-Standardized Mortality and Readmission after Hospitalization for Acute Myocardial Infarction. Heart Failure, and Pneumonia: Update on Publicly Reported Outcomes Measures Based on the 2013 Release. Journal of General Internal Medicine, 29, 1333-1340.  
&lt;br&gt;https://doi.org/10.1007/s11606-014-2862-5</mixed-citation></ref><ref id="hanspub.20798-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Spencer, F.A., Meyer, T.E., Gore, J.M. and Goldberg, R.J. (2002) Heterogeneity in the Management and Outcomes of Patients with Acute Myocardial Infarction Complicated by Heart Failure: The National Registry of Myocardial Infarction. Circulation, 105, 2605-2610. &lt;br&gt;https://doi.org/10.1161/01.CIR.0000017861.00991.2F</mixed-citation></ref><ref id="hanspub.20798-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Laura, P.A., Michela, D.R., Silvia, M., et al. (2010) Pro/Anti-Inflammatory Cytokine Imbalance in Post Ischemic Left Ventricular Remodeling. Mediators of Inflammation, 2010, Article ID: 974694. &lt;br&gt;https://doi.org/10.1155/2010/974694</mixed-citation></ref><ref id="hanspub.20798-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Wang, X., Lv, H., Gu, Y., et al. (2014) Protective Effect of Lycopene on Cardiac Function and Myocardial Fibrosis after Acute Myocardial Infarction in Rats via the Modulation of p38 and MMP-9. Journal of Molecular Histology, 45, 113-120. &lt;br&gt;https://doi.org/10.1007/s10735-013-9535-2</mixed-citation></ref><ref id="hanspub.20798-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Mohsen, M. and Shawky, A. (2015) The Diagnostic Utility of High-Sensitivity Cardiac Troponin T in Acute Coronary Syndrome. The Egyptian Heart Journal, 24, 1-9.</mixed-citation></ref><ref id="hanspub.20798-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Wang, J.A., Qin, Y., Lv, J., Tian, Y.F. and Dong, Y.J. (2015) Clinical Application of High-Sensitivity Cardiac Troponin T Test in Acute Myocardial Infarction Diagnosis. Genetics and Molecular Research, 14, 17959-17965.  
&lt;br&gt;https://doi.org/10.4238/2015.December.22.21</mixed-citation></ref><ref id="hanspub.20798-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">杜国有, 黄国强, 安辉, 等. 超敏肌钙蛋白I检测在急性冠状动脉综合征危险分层中的应用价值[J]. 国际检验医学杂志, 2014, 35(2), 182-183.</mixed-citation></ref><ref id="hanspub.20798-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Robert, T., Willemsen, A., Dinant, G.J. and Glatz, J.F.C. (2014) Heart-Type Fatty Acid Binding Protein (H-FABP) for the Early Evaluation of Suspected Acute Coronary. Biomarkers of Myocardial Cell Damage, 14, 1-31.</mixed-citation></ref><ref id="hanspub.20798-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Eurlings, L.W., Sanders-van Wilk, S., van Kraaij, D.J., et al. (2014) Risk Stratification with the Use of Serial N-Terminal Pro-B-Type Natriuretic Peptide Measurements during Admission and Early after Discharge in Heart Failure Patients: Post Hoc Analysis of the PRIMA Study. Journal of Cardiac Failure, 20, 881-890.  
&lt;br&gt;https://doi.org/10.1016/j.cardfail.2014.08.014</mixed-citation></ref><ref id="hanspub.20798-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Ribeiro, D.R.P., Ramos, A.M., Vieira, P.L., et al. (2014) High-Sensitivity C-Reactive Protein as a Predictor of Cardiovascular Events after ST-Elevation Myocardial Infarction. Arquivos Brasileiros de Cardiologia, 103, 69-75.</mixed-citation></ref><ref id="hanspub.20798-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Swiatkiewicz, I., Kozinski, M., Magielsk, P. et al. (2015) Value of C-Reactive Protein in Predicting Left Ventricular Remodelling in Patients with a First ST-Segment Elevation Myocardial Infarction. Circulation Research, 16, 368-384.</mixed-citation></ref><ref id="hanspub.20798-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Gururajan, P., Gurumurthy, P., Nayar, P., et al. (2012) Pregnancy Associated Plasma Protein-A (PAPP-A) as an Early Marker for the Diagnosis of Acute Coronary Syndrome. Indian Heart Journal, 64, 141-145.  
&lt;br&gt;https://doi.org/10.1016/s0019-4832(12)60049-2</mixed-citation></ref><ref id="hanspub.20798-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Khan, D.A., Sharif, M.S., et al. (2011) Diagnostic Performance of High-Sensitivity Troponin T, Myeloperoxidase, and Pregnancy-Associated Plasma Protein A Assays for Triage of Patients with Acute Myocardial Infarction. Korean Journal of Laboratory Medicine, 31, 172-178. &lt;br&gt;https://doi.org/10.3343/kjlm.2011.31.3.172</mixed-citation></ref><ref id="hanspub.20798-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Pascual-Figal, D.A., Manzano-Fernández, S., Boronat, M., et al. (2011) Soluble ST2, High-Sensitivity Troponin T- and N-Terminal Pro-B-type Natriuretic Peptide: Complementary Role for Risk Stratification in Acutely Decompensated Heart Failure. European Journal of Heart Failure, 13, 718-725. &lt;br&gt;https://doi.org/10.1093/eurjhf/hfr047</mixed-citation></ref><ref id="hanspub.20798-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Abdelmoneim, S.S., Martinez, M.W., et al. (2015) Resting Qualitative and Quantitative Myocardial Contrast Echocardiography to Predict Cardiac Events in Patients with Acute Myocardial Infarction and Percutaneous Revascularization. Heart and Vessels, 30, 45-55. &lt;br&gt;https://doi.org/10.1007/s00380-013-0460-9</mixed-citation></ref><ref id="hanspub.20798-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Souza, L.P., Campos, O., Peres, C.A., et al. (2011) Echocardiographic Predictors of Early In-Hospital Heart Failure during First ST-Elevation Acute Myocardial Infarction: Does Myocardial Performance Index and Left Atrial Volume Improve Diagnosis over Conventional Parameters of Left Ventricular Function? Cardiovascular Ultrasound, 9, 17.  
&lt;br&gt;https://doi.org/10.1186/1476-7120-9-17</mixed-citation></ref><ref id="hanspub.20798-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Westholm, C., Johnson, J., Sahlen, A., et al. (2013) Peak Systolic Velocity Using Color-Coded Tissue Doppler Imaging, a Strong and Independent Predictor of Outcome in Acute Coronary Syndrome Patients. Cardiovascular Ultrasound, 11, 19. &lt;br&gt;https://doi.org/10.1186/1476-7120-11-9</mixed-citation></ref><ref id="hanspub.20798-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Petrie, C.J., Voors, A.A., Robertson, M., et al. (2012) A Low Pulse Pressure Predicts Mortality in Subjects with Heart Failure after an Acute Myocardial Infarction: A Post-Hoc Analysis of the CAPRICORN Study. Clinical Research in Cardiology, 101, 29-35. &lt;br&gt;https://doi.org/10.1007/s00392-011-0360-x</mixed-citation></ref><ref id="hanspub.20798-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Shiraishi, J., Kohno, Y., Sawada, T., et al. (2013) Prognostic Impact of Pulse Pressure at Admission on In-Hospital Outcome after Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction. Heart and Vessels, 28, 434-441. &lt;br&gt;https://doi.org/10.1007/s00380-012-0277-y</mixed-citation></ref><ref id="hanspub.20798-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">邓长金, 彭娜, 成威, 等. 溶栓后PCI术与直接PCI术对急性心肌梗死患者近期心功能的影响[J]. 临床心血管病杂志, 2014, 30(9): 779-781.</mixed-citation></ref><ref id="hanspub.20798-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Wu, W., Huang, L., Zhang, J., et al. (2012) High-Frequency Ultrasound Evaluation of Effects of Early Treatment with Metoprolol on Myocardial Inflammatory Cytokine Expression in Rats with Acute Myocardial Infarction. Journal of Huazhong University of Science and Technology, 32, 774-778. &lt;br&gt;https://doi.org/10.1007/s11596-012-1033-3</mixed-citation></ref><ref id="hanspub.20798-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Pan, H.-Y., Zhu, J.-H., Gu, Y., et al. (2014) Comparative Effects of Recombinant Human Brain Natriuretic Peptide and Dobutamine on Acute Decompensated Heart Failure Patients with Different Blood BNP Levels. BMC Cardiovascular Disorders, 14, 31.</mixed-citation></ref><ref id="hanspub.20798-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Omerovic, E., Råmunddal, T., Albertsson, P., et al. (2010) Levosimendan Neither Improves nor Worsens Mortality in Patients with Cardiogenic Shock Due to ST-Elevation Myocardial Infarction. Vascular Health and Risk Management, 6, 657-663. &lt;br&gt;https://doi.org/10.2147/VHRM.S8856</mixed-citation></ref><ref id="hanspub.20798-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Polegato, B.F., Minicucci, M.F., et al. (2016) Association between Functional Variables and Heart Failure after Myocardial Infarction in Rats. Arquivos Brasileiros de Cardiologia, 106, 105-112.</mixed-citation></ref><ref id="hanspub.20798-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">宋艳东, 李志忠, 张京梅. CRRT对急性心肌梗死后心功能不全低血压状态患者疗效分析[J]. 中国血液净化杂志, 2013, 12(3): 130-133.</mixed-citation></ref><ref id="hanspub.20798-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Herdrich, B.J., Gorman, R.C. et al. (2010) Progenitor Cells for the Treatment of Acute Myocardial Infarction. Advances in Skin &amp; Wound Care, 1, 519-525.</mixed-citation></ref><ref id="hanspub.20798-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Flynn, A., Chen, X., O’Connell, E. and O’Brien, T. (2012) A Comparison of the Efficacy of Transplantation of Bone Marrow-Derived Mesenchymal Stem Cells and Unrestricted Somatic Stem Cells on Outcome after Acute Myocardial Infarction. Stem Cell Research &amp; Therapy, 3, 36. &lt;br&gt;https://doi.org/10.1186/scrt127</mixed-citation></ref><ref id="hanspub.20798-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Rodrigo, S.F., van Ramshorst, J., et al. (2013) Intramyocardial Injection of Autologous Bone Marrow-Derived ex Vivo Expanded Mesenchymal Stem Cells in Acute Myocardial Infarction Patients Is Feasible and Safe up to 5 Years of Follow-Up. Stem Cell Research &amp; Therapy, 6, 816-825. &lt;br&gt;https://doi.org/10.1007/s12265-013-9507-7</mixed-citation></ref></ref-list></back></article>